GLP-1 Based Therapeutics Summit: GLP-1 Receptor Agonists Beyond Weight Loss

I spent a week in Boston at the 3rd GLP-1-Based Therapeutics Summit, alongside colleagues from a remarkable cohort of emerging biotechs to imaging specialists and industry veterens such as ICON, AstraZenica and Eli Lilly - from both sides of the pond. Summarising the mentality of the room into a single sentence would be this: the industry has moved on from thinking of GLP-1s as weight loss drugs, that happen to do other things. We now consider them as pleiotropic medicines with a high potential to achieve much more.

Weight-loss was just the start

When GLP-1 receptors were first characterised, the early excitement centred on glycaemic control. Then came the weight loss data and cardiovascular findings. What we now understand is that none of this is incidental. GLP-1 receptors are distributed throughout the body; the heart, the kidneys, the brain, the liver - and the downstream effects of activating them are systemic.

The cardiovascular evidence is now substantial. Large-scale trials have demonstrated that GLP-1 receptor agonists reduce major adverse cardiovascular events by around 20% in patients with obesity or overweight, and crucially, that benefit holds consistently regardless of how much weight patients actually lose. Cardioprotection is not simply a consequence of shedding mass. It reflects direct anti-inflammatory effects, improved endothelial function, and plaque-stabilising properties that operate independently of the number on the scales. 

The kidney story is equally compelling. In patients with type 2 diabetes and chronic kidney disease, GLP-1s have demonstrated significant reductions in major kidney events, with mechanistic analyses pointing to suppression of inflammatory pathways and glomerular haemodynamic effects that go well beyond what adiposity reduction alone could explain. The regulatory response has followed: GLP-1 receptor agonists now carry dedicated indications for CKD, and current diabetes standards of care position them as preferred agents wherever cardiovascular or renal risk is the primary concern. 

And in Boston this week, the conversation moved further still. Heart failure with preserved ejection fraction, a condition that has historically resisted almost every therapeutic approach tried against it, is now showing meaningful signals of response. Obstructive sleep apnoea has received regulatory approval, the respiratory axis is opening. 

MASLD: The Field Reaches a Turning Point

The session that generated the most concentrated discussion, and the most honest conversation I've had at a summit in some time, was on MASLD and MASH.

Metabolic dysfunction-associated steatotic liver disease now affects more than a third of the global adult population. It is a major upstream driver of cirrhosis, hepatocellular carcinoma, cardiovascular disease, and chronic kidney disease. And it has historically been extraordinarily difficult to study, because confirming eligibility for a therapeutic trial has required liver biopsy - an invasive procedure that has produced screen failure rates of 70-80% in MASH programmes, as the confirmation process itself is a barrier. 

The FDA's recent acceptance of liver stiffness measurement by vibration-controlled transient elastography as a reasonably likely surrogate endpoint for MASH trials has changed the landscape materially. The field is moving toward non-invasive tests - elastography, FIB-4 scoring, advanced serum biomarker panels - as the entry point for trial participation. Combined with the August 2025 approval of semaglutide for MASH with moderate-to-advanced fibrosis (the ESSENCE trial showing genuine resolution of scarring, not merely stabilisation), this disease area is entering a new phase of clinical intensity. 

The GLP-1 Question the Science Now Forces 

The therapeutic ambition has expanded dramatically across CKD, MASH, respiratory, CNS, women's health. And with that expansion comes a more complex and diverse set of patients, all of whom are in communities. Historically these patients have been underserved by clinical research infrastructure, and patients for whom travelling to a tertiary site for a screening biopsy was already an huge ask. The new non-invasive pathways, and flexible community-based site networks now represent something genuinely different. 

That is the strategic conversation I found myself in, with sponsors and colleagues on the floor this week. The science and regulatory environment is moving. The remaining constraint is inclusion, and whether the populations who carry the highest burden of these conditions can actually get into the trials. 

The UK's position in this conversation is strong, and I don't think it is fully appreciated yet. The regulatory environment here remains among the fastest in the world for trial initiation. The NHS creates longitudinal, linked patient data of a kind that fragmented systems elsewhere cannot replicate. We have the infrastructure to put community research sites into underserved regions, reaching patients where they are, with the trust and relationships that retention requires. 

For sponsors building MASLD, CKD, neuro-metabolic, and women's health programmes for 2026 and 2027, that combination is not merely convenient: it is the answer to the most pressing question for those in this space.

Follow Dr Nick Probert on LinkedIn for the latest clinical research insights.